Healthcare
Live Price
Offline$30.08
+0.03% today
1Y Change
+4.94%
Window
Jun 23, 2025 → Jun 5, 2026
Coverage: 240 bars · Jun 23, 2025 → Jun 5, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Smith & Nephew plc (SNN) is a Healthcare stock with a market cap of $13.28B and listed on NYSE. The stock last traded around $30.08 and up 4.9% across the available one-year price window (Jun 23, 2025 → Jun 5, 2026). Baseline metrics include revenue growth of +6.3%, EPS growth of +55.3%, a dividend yield of 2.5%. What stands out right now is revenue +6.3%, EPS +55.3%, free cash flow +40.9% with operating margin 16.3% and ROIC 9.1%. The dividend matters to the case here, with a current yield around 2.5%. Valuation is more restrained than many high-expectation growth names at P/E 21.2 and price/sales 2.1. Stock Foundry combines SNN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SNN
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SNN Max Drawdown
-24.81%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SNN and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$5.2B
-0.1% YoY
FY Net Income
$524.0M
+135.0% YoY
Free Cash Flow
$469.0M
+326.4% YoY
Revenue Growth
+6.3%
EPS Growth
+55.3%
Gross Margin
68.0%
Net Margin
10.1%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 6.2B | 5.8B | 5.5B | 5.2B | 5.2B |
| Gross Profit | 4.2B | 4.0B | 3.8B | 3.7B | 3.7B |
| Operating Income | 1.0B | 657M | 425M | 315M | 593M |
| EBITDA | 1.6B | 1.2B | 956M | 874M | 1.2B |
| Net Income | 626M | 412M | 263M | 223M | 524M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 557M | 619M | 302M | 350M | 1.3B |
| Total Assets | 10.5B | 10.4B | 10.0B | 10.0B | 10.9B |
| Total Liabilities | 5.2B | 5.1B | 4.8B | 4.7B | 5.4B |
| Shareholder Equity | 5.3B | 5.3B | 5.2B | 5.3B | 5.6B |
| Total Debt | 3.3B | 3.3B | 3.1B | 2.9B | 3.3B |
| Net Debt | 2.8B | 2.7B | 2.8B | 2.5B | 2.0B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
877M
+87.4% YoY
Capital Expenditures
408M
-14.0% YoY
Free Cash Flow
469M
+326.4% YoY
Key ratios
Gross Margin
68.0%
Operating Margin
16.3%
Net Margin
10.1%
ROE
11.8%
Debt / Equity
0.63x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.